Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma (M032-HSV-1)

Clinical Trial ID NCT02062827

Rank	Title	Journal	Year	PubWeight™‹?›
1	Sui generis: gene therapy and delivery systems for the treatment of glioblastoma.	Neuro Oncol	2015	0.94
2	What next for newly diagnosed glioblastoma?	Future Oncol	2015	0.94
3	Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy.	Front Microbiol	2014	0.87
4	EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA.	Drugs Future	2016	0.84
5	Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.	Neuro Oncol	2015	0.84
6	Gene therapy for malignant glioma.	Mol Cell Ther	2014	0.83
7	Retargeting Strategies for Oncolytic Herpes Simplex Viruses.	Viruses	2016	0.80
8	Designing Herpes Viruses as Oncolytics.	Mol Ther Oncolytics	2015	0.79
9	Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.	Mol Ther Oncolytics	2015	0.77
10	Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"?	Mol Ther Oncolytics	2015	0.77
11	Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma.	Transl Oncol	2016	0.75
12	Oncolytic virotherapy for pediatric malignancies: future prospects.	Oncolytic Virother	2016	0.75